HRP20010036B1 - Neurotrophic growth factor - Google Patents

Neurotrophic growth factor

Info

Publication number
HRP20010036B1
HRP20010036B1 HR20010036A HRP20010036A HRP20010036B1 HR P20010036 B1 HRP20010036 B1 HR P20010036B1 HR 20010036 A HR20010036 A HR 20010036A HR P20010036 A HRP20010036 A HR P20010036A HR P20010036 B1 HRP20010036 B1 HR P20010036B1
Authority
HR
Croatia
Prior art keywords
growth factor
neurotrophic growth
seq
amino acid
encoding
Prior art date
Application number
HR20010036A
Other languages
English (en)
Croatian (hr)
Inventor
Alfons Gabriel Geerts Hugo
Leo Jozef Masure Stefan
Frans Meert Theo
Cik Miroslav
Donck Luc Ver
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20010036(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9815283.8A external-priority patent/GB9815283D0/en
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20010036A2 publication Critical patent/HRP20010036A2/hr
Publication of HRP20010036B1 publication Critical patent/HRP20010036B1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
HR20010036A 1998-07-14 2001-01-12 Neurotrophic growth factor HRP20010036B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9815283.8A GB9815283D0 (en) 1998-07-14 1998-07-14 Neurotrophic growth factor
US24877299A 1999-02-12 1999-02-12
US32766899A 1999-06-08 1999-06-08
PCT/EP1999/005031 WO2000004050A2 (en) 1998-07-14 1999-07-14 Neurotrophic growth factor

Publications (2)

Publication Number Publication Date
HRP20010036A2 HRP20010036A2 (en) 2001-12-31
HRP20010036B1 true HRP20010036B1 (en) 2010-06-30

Family

ID=27269394

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010036A HRP20010036B1 (en) 1998-07-14 2001-01-12 Neurotrophic growth factor

Country Status (28)

Country Link
US (1) US7544788B2 (zh)
EP (2) EP1097167B2 (zh)
JP (2) JP4469500B2 (zh)
KR (2) KR100773776B1 (zh)
CN (1) CN1243770C (zh)
AT (1) ATE343594T1 (zh)
AU (1) AU768472B2 (zh)
BG (1) BG65518B1 (zh)
BR (2) BRPI9912819B8 (zh)
CA (1) CA2333910C (zh)
CY (2) CY1105949T1 (zh)
CZ (1) CZ303868B6 (zh)
DE (1) DE69933771T2 (zh)
DK (2) DK1640381T3 (zh)
ES (2) ES2275349T3 (zh)
HK (2) HK1045528B (zh)
HR (1) HRP20010036B1 (zh)
HU (1) HU226073B1 (zh)
ID (1) ID27024A (zh)
IL (1) IL140877A0 (zh)
NO (1) NO331809B1 (zh)
NZ (1) NZ509723A (zh)
PL (1) PL209952B1 (zh)
PT (2) PT1097167E (zh)
SI (1) SI1640381T1 (zh)
SK (1) SK287361B6 (zh)
TR (1) TR200100074T2 (zh)
WO (1) WO2000004050A2 (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9911908A (pt) * 1998-07-06 2001-03-27 Nsgene As ácido nucléico, sequência de ácido nucléico, processos de usar um ácido nucléico, de usar o vetor, de fabricar o polipeptìdeo, de administrar o polipeptìdeo, de tratar uma doença ou distúrbio neurodegenerativos em um animal, de determinar se uma doença ou distúrbio neurodegenerativos em um animal, de produzir qualquer um polipeptìdeo, processo para identificar, isolar ou amplificar uma sequência de ácido nucléico de neublastina, de diagnosticar ou avaliar quanto a presença de uma doença ou distúrbio ou uma predisposiçãopara desnvolvê-los, para avaliar um polipeptìdeo de neublastina purificado ou um derivado ou fragmento deste ou um modulador da atividade dos precedentes quanto a atividade em tratar ou prevenir uma doença, de tratar um distúbio neurológico, de usar a sequência de um ou mais ácidos nucléicos, e para identificar um composto candidato que induza um efeito biológico mediado pela neuroblastina, vetor, célula transformada com ácido nucléico, polipeptìdeo, cmposição, anticorpo, gene sintético, e, conjunto.
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US7067473B1 (en) 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
ES2275349T3 (es) * 1998-07-14 2007-06-01 Janssen Pharmaceutica N.V. Factor de crecimiento neurotrofico.
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
AU2354600A (en) * 1998-12-09 2000-06-26 Amgen, Inc. Grnf4 a neurotrophic factor
EP1867719A3 (en) * 1999-06-02 2008-03-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
KR20080067719A (ko) * 2000-12-22 2008-07-21 제넨테크, 인크. Ｇｄｎｆ 리간드 족의 구성원인 아르테민의 신규 용도
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
ATE526982T1 (de) * 2001-03-28 2011-10-15 Biogen Idec Inc Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen
US20040077543A1 (en) * 2001-03-28 2004-04-22 Sah Dinah W. Y. Treatment using neublastin polypeptides
PL371596A1 (en) * 2002-05-17 2005-06-27 Merck Patent Gmbh Use of compounds that are effective as selective opiate receptor modulators
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
CA2522364C (en) 2003-04-18 2014-12-09 Biogen Idec Ma Inc. Polymer-conjugated glycosylated neublastin
ES2323066T3 (es) 2003-06-10 2009-07-06 Nsgene A/S Secrecion mejorada de neublastina.
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
CN101123978B (zh) 2004-08-19 2012-12-12 比奥根艾迪克Ma公司 神经胚素变体
CA2577755C (en) * 2004-08-19 2014-05-13 Biogen Idec Ma Inc. Neublastin variants
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2007103182A2 (en) * 2006-03-01 2007-09-13 Biogen Idec Ma Inc. Compostions and methods for administering gdnf ligand family proteins
JP5829377B2 (ja) 2007-02-06 2015-12-09 ジュン ヨー，タイ 遺伝子治療を使用する神経変性疾患の治療および予防
WO2008137574A1 (en) 2007-05-01 2008-11-13 Biogen Idec Ma Inc. Compositions and methods for increasing vascularization
US20110206673A1 (en) * 2007-06-27 2011-08-25 Liu Dongxu Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
US20110135648A1 (en) * 2007-08-08 2011-06-09 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
US11225689B2 (en) * 2016-08-17 2022-01-18 The Broad Institute, Inc. Method for determination and identification of cell signatures and cell markers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001815A2 (en) * 1998-07-06 2000-01-13 Nsgene A/S Neurotrophic factors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US7067473B1 (en) 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
ES2275349T3 (es) * 1998-07-14 2007-06-01 Janssen Pharmaceutica N.V. Factor de crecimiento neurotrofico.
US6284540B1 (en) 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
AU2354600A (en) † 1998-12-09 2000-06-26 Amgen, Inc. Grnf4 a neurotrophic factor
JP2002051906A (ja) * 2000-08-11 2002-02-19 Nippon Platec Co Ltd Ｉｈ調理器による加熱を可能にしたアルミ箔材料及びこのアルミ箔材料を用いて成形したアルミ箔材料製食品用容器
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
WO2018191688A2 (en) † 2017-04-14 2018-10-18 Johnson Controls Techology Company Thermostat with exhaust fan control for air quality and humidity control

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001815A2 (en) * 1998-07-06 2000-01-13 Nsgene A/S Neurotrophic factors

Also Published As

Publication number Publication date
HK1045528B (zh) 2006-10-27
AU5283299A (en) 2000-02-07
BG105107A (en) 2001-10-31
ATE343594T1 (de) 2006-11-15
ES2479067T3 (es) 2014-07-23
NO331809B1 (no) 2012-04-10
HUP0102821A2 (hu) 2001-11-28
EP1640381B1 (en) 2014-05-14
US20050233359A1 (en) 2005-10-20
SI1640381T1 (sl) 2014-07-31
KR20060061408A (ko) 2006-06-07
US7544788B2 (en) 2009-06-09
EP1097167B1 (en) 2006-10-25
CA2333910C (en) 2016-11-15
BG65518B1 (bg) 2008-10-31
PL348431A1 (en) 2002-05-20
SK287361B6 (sk) 2010-08-09
HRP20010036A2 (en) 2001-12-31
DE69933771D1 (de) 2006-12-07
IL140877A0 (en) 2002-02-10
DK1640381T3 (da) 2014-07-14
AU768472B2 (en) 2003-12-11
EP1097167B2 (en) 2018-12-12
NZ509723A (en) 2004-01-30
CN1243770C (zh) 2006-03-01
ID27024A (id) 2001-02-22
TR200100074T2 (tr) 2001-11-21
EP1640381A2 (en) 2006-03-29
CN1342165A (zh) 2002-03-27
CZ303868B6 (cs) 2013-06-05
KR20010083108A (ko) 2001-08-31
CY1115496T1 (el) 2017-01-04
SK142001A3 (en) 2002-02-05
PL209952B1 (pl) 2011-11-30
JP4469500B2 (ja) 2010-05-26
EP1097167A2 (en) 2001-05-09
BRPI9912819B1 (pt) 2018-09-18
WO2000004050A2 (en) 2000-01-27
WO2000004050A3 (en) 2000-11-09
HU226073B1 (en) 2008-04-28
NO20010212D0 (no) 2001-01-12
EP1640381A3 (en) 2007-01-31
BRPI9912819B8 (pt) 2021-05-25
CA2333910A1 (en) 2000-01-27
PT1640381E (pt) 2014-07-17
KR100773776B1 (ko) 2007-11-12
HUP0102821A3 (en) 2003-09-29
CZ200128A3 (cs) 2001-08-15
CY1105949T1 (el) 2011-04-06
JP2002520042A (ja) 2002-07-09
BR9912819A (pt) 2001-05-02
ES2275349T3 (es) 2007-06-01
KR100712223B1 (ko) 2007-04-27
DE69933771T2 (de) 2007-09-13
DK1097167T3 (da) 2007-03-12
HK1045528A1 (en) 2002-11-29
JP2010158241A (ja) 2010-07-22
JP4624476B2 (ja) 2011-02-02
HK1092477A1 (en) 2007-02-09
NO20010212L (no) 2001-03-14
PT1097167E (pt) 2007-02-28

Similar Documents

Publication Publication Date Title
HRP20010036B1 (en) Neurotrophic growth factor
RS50364B (sr) Modifikovani faktor viii
IS2636B (is) Stilliefni fyrir endurmyndun vefja
TW327194B (en) Novel amyloid precursor proteins and methods of using same
CY1109978T1 (el) Αντιγονικα πεπτιδια εξαγομενα απο τελομεραση
AUPP051497A0 (en) Antimicrobial peptides
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
CY1106978T1 (el) Ενζυμα φωσφοδιεστερασης
NO974035D0 (no) En ny vestfaktor og en genetisk sekvens som koder for denne
EP1548107A4 (en) CHROMOPROTEIN AND FLUOROPROTEINS
EP0763105A4 (en) ISOLATED NUCLEIC ACID MOLECULE ENCODING FIBROBLASTE ACTIVATION PROTEIN -g (a) AND USES
EP1037999A4 (en) POLYPEPTIDES AND NUCLEOTIDES PORPHYROMONAS GINGIVALIS
HUP9904414A2 (hu) A neuritin neurogén
IL142709A0 (en) Novel amino acid sequences, dna encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof
EP0816504A3 (en) Platelet activating factor acetylhdrolase, and gene thereof
ATE348158T1 (de) Neuartiges collectin
GB9416536D0 (en) Orphan receptor
AU2043597A (en) Human taki dna encoding the same
CA2244928A1 (en) Dna coding for serine/threonine kinase
WO2001092468A3 (en) Novel compositions for the expression of the human peptide histidine transporter 1 and methods of use thereof
EP0803571A3 (en) Tab1 protein & dna coding therefor
EP1013665A4 (en) NEW POLYPEPTIDE DEPLOYING WATER CIRCULATION ACTIVITY AND DNA SEQUENCE
EP1158052A4 (en) BETA-PRIMEVEROSIDASDE GENE
YU29801A (sh) Gen prv-1 i njegova primena
CA2188264A1 (en) Isolated nucleic acid molecule coding for fibroblast activation protein .alpha. and uses thereof

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20180626

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20190717